Validation of a method to estimate direct normal irradiance of UVA and PAR bands from global horizontal measurements for cloudless sky conditions in Valencia, Spain, by a measurement campaign

A method is proposed to provide measurement of direct normal solar irradiance of bands with wavelength ranges (315-400 nm, 400-700 nm) from measurements of global horizontal band irradiance for cloudless sky conditions in Valencia. Global and normal direct irradiance data for every air mass were obtained by applying the SMART2 model to the atmosphere of Valencia. The direct normal to global irradiance ratio was parameterized versus the relative optical air mass. A measurement campaign of global horizontal and diffuse irradiance of UVA and PAR bands was carried out in Valencia, after which, the inferred direct normal irradiance was compared with those provided by the method. The result of the comparison shows that the method is acceptably accurate. The proposed model tends to underestimate the direct normal irradiance of the UVA band by 6%, although for values below 25 W/m2 the model overestimates the direct irradiance by 6%, while for values above 25 W/m2 the model underestimates it by 10%. The other two error estimators used ranging from 11% to 15% are similar in the defined interval measurements in relation to the whole UVA band. Regarding the PAR band, the model overestimates the direct normal irradiance of the PAR band by only 2.2%. With this, the results of the PAR band are more conclusive, as it has been found that for direct normal irradiance values higher than 280 W/m2 the MBE error is almost zero and the other two estimator errors are small, about 5%. © 2010 Springer-Verlag.This work was supported by the Spanish Government through MEC grant MAT2009-14625-C03-03, and is a part of the activities of the Grup d'Optoelectronica i Semiconductors of the Polytechnic University of Valencia. The translation of this paper was funded by the Universidad Politecnica de Valencia, Spain.Serrano Jareño, MA.; Boscá Berga, JV. (2011). Validation of a method to estimate direct normal irradiance of UVA and PAR bands from global horizontal measurements for cloudless sky conditions in Valencia, Spain, by a measurement campaign. Theoretical and Applied Climatology. 103(1):95-101. https://doi.org/10.1007/s00704-010-0284-9S951011031Barth J, Cadet J, Césarini JP, Fitzpatrick TB, McKinlay A, Mutzhas M, Pathak M, Peak M, Sliney D, Urbach F (1999) TC 6-26 report: Standardization of the terms UV-A1, UV-A2 and UV-B, CIE 134-1999 ISBN 3-900-734-94-1Batlles FJ, Olmo FJ, Alados-Arboledas L (1995) On shadowband correction methods for diffuse irradiance measurements. Solar Energy 54(5):105–114Drummond AJ (1956) On the measurement of sky radiation. Arch 602 Meteor Geophys Bioklim B 7:413–436Gueymard C (1995) SMARTS2: a simple model of the atmospheric radiative transfer of sunshine: algorithms and performance assessment. FSEC-PF-270-95, Florida Solar Energy CenterGueymard C (2003) SMARTS2 code, versión 2.9.2. User’s Manual, Solar Consulting Services Bailey CO. Available from http://rredc.nrel.gov/solar/models/SMARTS/smarts_index.htmlGueymard C (2004) The sun’s total and spectral irradiance for solar energy applications and solar radiation models. Solar Energy 76:423–453Häder DP, Lebert M, Marangoni R, Colombetti G (1999) ELDONET-European light dosimeter network hardware and software. J Photochem Photobiol B: Biol 52:51–58Häder DP, Lebert M, Colombetti G, Figueroa F (2001) European light dosimeter network (ELDONET). Helgol Mar Res 55:35–44Iqbal M (1983) An introduction to solar radiation. Academic, TorontoKudish AI, Evseev EG (2008) The assessment of four different correction models applied to the diffuse radiation measured with a shadow ring using global and normal beam radiation measurements for Beer Sheva, Israel. Solar Energy 82(2):144–156LeBaron BA, Michalsky JJ, Perez R (1990) A simple procedure for correcting shadowband data for all sky conditions. Solar Energy 44:249–256Marín Fernández MJ (2007) Estudio de la irradiancia solar ultravioleta y eritemática en la Comunidad Valenciana. Doctoral Thesis University of Valencia (Spain)Perez R, Ineichen P, Seals R, Michalsky JJ, Stewart R (1990) Modelling daylight availability and irradiance components from direct and global irradiance. Sol Energy 44:271–289Pinazo JM, Cañada J, Bosca JV (1995) A new method to determine Ångström's turbidity coefficient: its application for Valencia. Solar Energy 54:219–226Serrano MA, Boscá JV, Cañada J (2008) The determination of a band factor to express irradiance of UV and PAR wavelength ranges in a clean and dry atmosphere at Valencia (Spain). Int J Ambient Energy 29(4):171–180Utrillas MP, Boscà JV, Martinez-Lozano JA, Cañada J, Tena F, Pinazo JM (1998) A comparative study of Spectral2, and Smarts2 parameterised models based on spectral irradiance measurements at Valencia, Spain. Solar Energy 63:161–171Utrillas MP, Marín MJ, Esteve AR, Tena F, Cañada J, Estellés V, Martínez Lozano JA (2007) Diffuse UV erythemal radiation experimental values. J Geophy Res 112:387–39

Fingolimod: therapeutic mechanisms and ocular adverse effects.

Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). We aim to review the published literature on ocular manifestations of fingolimod therapy and their possible underlying mechanisms. The therapeutic effects of fingolimod are mediated via sphingosine receptors, which are found ubiquitously in various organs, including lymphoid cells, central nervous system, cardiac myocytes, and smooth muscle cells. Fingolimod-associated macular oedema (FAME) is the most common ocular side effect but retinal haemorrhages and retinal vein occlusion can occur. The visual consequences appear to be mild and, in cases of FAME, resolution is often attained with discontinuation of therapy. However, in cases of retinal vein occlusion, discontinuation of fingolimod alone may not be sufficient and intra-vitreal therapy may be required. We also propose a pragmatic service pathway for monitoring patients on fingolimod therapy, which includes stratifying them by risk and visual acuity

Short-term follow-up of chagasic patients after benznidazole treatment using multiple serological markers

<p>Abstract</p> <p>Background</p> <p>Conventional serological tests, using total soluble proteins or a cocktail of recombinant proteins from <it>T. cruzi </it>as antigens, are highly sensitive for Chagas disease diagnosis. This type of tests, however, does not seem to be reliable tools for short- and medium-term monitoring of the evolution of patients after antiparasitic treatment. The aim of the present study was to search for immunological markers that could be altered in the sera from Chagas disease patients after benznidazole treatment, and therefore have a potential predictive diagnostic value.</p> <p>Methods</p> <p>We analyzed the reactivity of sera from chagasic patients during different clinical phases of the disease against a series of immunodominant antigens, known as KMP11, PFR2, HSP70 and Tgp63. The reactivity of the sera from 46 adult Chronic Chagas disease patients living in a non-endemic country without vector transmission of <it>T. cruzi </it>(15 patients in the indeterminate stage, 16 in the cardiomiopathy stage and 16 in the digestive stage) and 22 control sera from non-infected subjects was analyzed. We also analyzed the response dynamics of sera from those patients who had been treated with benznidazole.</p> <p>Results</p> <p>Regardless of the stage of the sickness, the sera from chagasic patients reacted against KMP11, HSP70, PFR2 and Tgp63 recombinant proteins with statistical significance relative to the reactivity against the same antigens by the sera from healthy donors, patients with autoimmune diseases or patients suffering from tuberculosis, leprosy or malaria. Shortly after benznidazole treatment, a statistically significant decrease in reactivity against KMP11, HSP70 and PFR2 was observed (six or nine month). It was also observed that, following benznidazole treatment, the differential reactivity against these antigens co-relates with the clinical status of the patients.</p> <p>Conclusions</p> <p>The recombinant antigens KMP11, PFR2, Tgp63 and HSP70 are recognized by Chagas disease patients' sera at any clinical stage of the disease. Shortly after benznidazole treatment, a drop in reactivity against three of these antigens is produced in an antigen-specific manner. Most likely, analysis of the reactivity against these recombinant antigens may be useful for monitoring the effectiveness of benznidazole treatment.</p

2 nd Brazilian Consensus on Chagas Disease, 2015

Abstract Chagas disease is a neglected chronic condition with a high burden of morbidity and mortality. It has considerable psychological, social, and economic impacts. The disease represents a significant public health issue in Brazil, with different regional patterns. This document presents the evidence that resulted in the Brazilian Consensus on Chagas Disease. The objective was to review and standardize strategies for diagnosis, treatment, prevention, and control of Chagas disease in the country, based on the available scientific evidence. The consensus is based on the articulation and strategic contribution of renowned Brazilian experts with knowledge and experience on various aspects of the disease. It is the result of a close collaboration between the Brazilian Society of Tropical Medicine and the Ministry of Health. It is hoped that this document will strengthen the development of integrated actions against Chagas disease in the country, focusing on epidemiology, management, comprehensive care (including families and communities), communication, information, education, and research

Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives

The definition of a biomarker provided by the World Health Organization is any substance, structure, or process that can be measured in the body, or its products and influence, or predict the incidence or outcome of disease. Currently, the lack of prognosis and progression markers for chronic Chagas disease has posed limitations for testing new drugs to treat this neglected disease. Several molecules and techniques to detect biomarkers in Trypanosoma cruzi-infected patients have been proposed to assess whether specific treatment with benznidazole or nifurtimox is effective. Isolated proteins or protein groups from different T. cruzi stages and parasite-derived glycoproteins and synthetic neoglycoconjugates have been demonstrated to be useful for this purpose, as have nucleic acid amplification techniques. The amplification of T. cruzi DNA using the real-time polymerase chain reaction method is the leading test for assessing responses to treatment in a short period of time. Biochemical biomarkers have been tested early after specific treatment. Cytokines and surface markers represent promising molecules for the characterisation of host cellular responses, but need to be further assessed.RICET RD12/0018/0010. RICET RD12/0018/0021. AGAUR 2014SGR26. Plan Nacional de I+D+I SAF2012-35777. Plan Nacional de I+D+I SAF2013-48527-R. NIMHD/NIH 2G12MD007592. Financial support: CRESIB and IPBLN research members were partially supported by the RICET (RD12/0018/0010, RD12/0018/0021), M-JP and JG received research funds from AGAUR (2014SGR26) and Fundación Mundo Sano, M-CT and M-CL were supported by Plan Nacional de I+D+I (MINECO-Spain) (SAF2012-35777, SAF2013-48527-R and FEDER), ICA was partially supported by NIMHD/NIH (2G12MD007592). Financial support: CRESIB and IPBLN research members were partially supported by the RICET (RD12/0018/0010, RD12/0018/0021), M-JP and JG received research funds from AGAUR (2014SGR26) and Fundación Mundo Sano, M-CT and M-CL were supported by Plan Nacional de I+D+I (MINECO-Spain) (SAF2012-35777, SAF2013-48527-R and FEDER), ICA was partially supported by NIMHD/NIH (2G12MD007592).Peer reviewe

Differential Phenotypic and Functional Profiles of TcCA-2 -Specific Cytotoxic CD8+ T Cells in the Asymptomatic versus Cardiac Phase in Chagasic Patients

It has been reported that the immune response mediated by T CD8+ lymphocytes plays a critical role in the control of Trypanosoma cruzi infection and that the clinical symptoms of Chagas disease appear to be related to the competence of the CD8+ T immune response against the parasite. Herewith, in silico prediction and binding assays on TAP-deficient T2 cells were used to identify potential HLA-A*02:01 ligands in the T. cruzi TcCA-2 protein. The TcCA-2-specific CD8+ T cells were functionality evaluated by Granzyme B and cytokine production in peripheral blood mononuclear cells (PBMC) from Chagas disease patients stimulated with the identified HLA-A*02:01 peptides. The specific cells were phenotypically characterized by flow cytometry using several surface markers and HLA-A*02:01 APC-labeled dextramer loaded with the peptides. In the T. cruzi TcCA-2 protein four T CD8+ epitopes were identified which are processed and presented during Chagas disease. Interestingly, a differential cellular phenotypic profile could be correlated with the severity of the disease. The TcCA-2-specific T CD8+ cells from patients with cardiac symptoms are mainly effector memory cells (TEM and TEMRA) while, those present in the asymptomatic phase are predominantly naive cells (TNAIVE). Moreover, in patients with cardiac symptoms the percentage of cells with senescence features is significantly higher than in patients at the asymptomatic phase of the disease. We consider that the identification of these new class I-restricted epitopes are helpful for designing biomarkers of sickness pathology as well as the development of immunotherapies against T. cruzi infection.This work was supported by grants SAF2012-35777 and SAF2013-48527-R from Programa Estatal I+D+i (MINECO); Network of Tropical Diseases Research RICET, grants RD12/0018/0021 and RD12/0018/0018 (MSSSI, Spain) and FEDER. MS and BC were also supported by grant FIS, 2009SGR385 from ISCIII (MSSSI, Spain). Coauthor Concepción Marañón is employed by Genomic Medicine Department, GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government provided support in the form of salaries for author Concepción Marañón, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the author contributions section.Peer reviewe